Clinical Trial Detail

NCT ID NCT03516591
Title A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amphivena Therapeutics, Inc.
Indications

myelodysplastic syndrome

Therapies

AMV-564

Age Groups: adult senior

No variant requirements are available.